TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Barclays PLC

Barclays PLC decreased its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 8.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 317,563 shares of the biopharmaceutical company’s stock after selling 29,494 shares during the period. Barclays PLC’s holdings in TG Therapeutics were worth $9,559,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Quadrant Capital Group LLC grew its stake in shares of TG Therapeutics by 137.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company’s stock valued at $51,000 after purchasing an additional 975 shares during the last quarter. Blue Trust Inc. grew its position in TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 371 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 1,594 shares during the period. Jones Financial Companies Lllp raised its position in TG Therapeutics by 460.7% during the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company’s stock worth $64,000 after buying an additional 1,737 shares during the last quarter. Finally, Synergy Asset Management LLC acquired a new stake in shares of TG Therapeutics in the 4th quarter worth $75,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

TGTX has been the subject of several analyst reports. StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $40.67.

TG Therapeutics Trading Up 2.8 %

Shares of TGTX opened at $37.99 on Wednesday. The firm’s 50-day moving average is $36.61 and its two-hundred day moving average is $32.13. TG Therapeutics, Inc. has a twelve month low of $12.93 and a twelve month high of $43.32. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The firm has a market capitalization of $5.97 billion, a P/E ratio of -379.86 and a beta of 2.14.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. The firm had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. On average, research analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.